Dr. Lingmi Hou 侯令密
Chief Physician, Associate Professor
Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized surgical treatment for breast and thyroid cancer, including mastectomy, breast-conserving surgery with prosthetic reconstruction, scarless benign tumor removal, thyroid cancer lymph node dissection, and surgical treatment of secondary hyperparathyroidism.
Dr. Hou holds a medical doctorate and serves as Chief Physician and Associate Professor at Sichuan Cancer Hospital. A visiting scholar at Wayne State University, Dr. Hou supervises master’s and doctoral students. The doctor has published over 30 SCI papers as first or corresponding author and received the Second Prize of the Sichuan Medical Science and Technology Award.
Professional roles
- Standing Committee Member, Breast and Thyroid Professional Committee, Rehabilitation Branch, China Anti-Cancer Association
- Member, Breast Professional Committee, Chinese Research Hospital Association
- Vice Chair, Thyroid Surgery Branch, Sichuan Medical Doctor Association
- Vice Chair, Medical Science Popularization Branch, Sichuan Medical Doctor Association
Name order: in Chinese the family name comes first (Hou Lingmi). Papers usually list the name as Lingmi Hou or Hou L.
Selected publications
16 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mater Today Bio, 2025 (senior author): A selective RCC1 inhibitor loaded in membrane-coated DNA nanocage for targeted suppression of TNBC progression. PubMed 40969389
- Discov Oncol, 2025 (senior author): Global trends and research hotspots in autophagy and tumor drug resistance: a bibliometric analysis. PubMed 40354002
- Mater Today Bio, 2025 (senior author): A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression. PubMed 39906202
- ACS Nano, 2022 (first author): Targeted Intervention of NF2-YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC. PubMed 35420780
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion